Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy of luspatercept in reducing transfusion burden and its impact on liver iron concentration in beta-thalassemia major: A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAnnaliz Flores-Saldivar

Discussion

Loading...

Member takes

Overview

Systematic review shows luspatercept reduces transfusion burden in beta-thalassemia, indicating its potential as a therapeutic agent.

Key Points

  • Evaluate the efficacy of luspatercept in reducing transfusion burden and liver iron concentration in beta-thalassemia major patients.
  • Systematic search in Pubmed, Embase and Cochrane for relevant studies.
  • Comparison of luspatercept versus placebo in transfusion-dependent beta-thalassemia patients.
  • Outcomes measured included reduction in transfusion burden and liver iron concentration.
  • 368 patients included from two clinical trials.
  • Luspatercept led to a higher proportion of patients achieving ≥33% (RR = 2.22) and ≥50% (RR = 6.22) reduction in transfusion burden compared to placebo.
  • No significant difference in liver iron concentration (mean difference: 1.33 mg/g; p = 0.22).

Cite This Study

Annaliz Flores-Saldivar (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2c7https://doi.org/10.1182/blood-2025-6475
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes with luspatercept in patients with β-thalassemia: a systematic review and meta-analysis2026
  2. 2Outcomes with luspatercept in patients with β-thalassemia: A systematic review and meta-analysis2025
  3. 3Luspatercept in β-thalassemia: Meta-analysis of efficacy and safety across transfusion-dependent and non-transfusion-dependent populations2025
  4. 4Transfusion independence in thalassemia patients after failure of gene therapy or with hemoglobin h constant spring and hb e using luspatercept: A case series2025
  5. 5Luspatercept (REBLOZYL): A Game-Changer in Reducing Transfusion Burden for <i>β</i>-Thalassemia Patients2025